Skip to content
1st Counsel – Lifestyle
Author:
Moderna, Inc.
Moderna Reports Third Quarter 2026 Financial Results and Provides Business Updates
November 6, 2026
Health Canada Authorizes Moderna’s mRNA Influenza and Combination Influenza and COVID-19 Vaccines
November 5, 2026
Moderna Advances Investigational Bundibugyo Ebolavirus Vaccine Toward Phase 2/3 Study
November 4, 2026
Moderna Named a Top Employer by Science for Twelfth Consecutive Year
October 23, 2026
Moderna to Report Third Quarter 2026 Financial Results on Friday, November 6, 2026
October 13, 2026
Moderna Adds Chief Operating Officer Role as Company Expands into Oncology
September 30, 2026
Moderna Announces Late-Breaking Data to be Presented at ESMO Congress 2026
September 21, 2026
Moderna to Present at Upcoming Conferences in September 2026
September 1, 2026
Moderna Announces Proposed Private Placement of $2.0 Billion of Convertible Senior Notes
August 27, 2026
Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA
August 5, 2026
1
2
3
Next Page
→